Shares of BioLineRx Ltd. (NASDAQ:BLRX) have been assigned an average broker rating score of 2.00 (Buy) from the two brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. BioLineRx’s rating score has declined by 100% in the last three months as a result of various analysts’ ratings changes.
Brokers have set a twelve-month consensus price objective of $4.00 for the company and are predicting that the company will post ($0.07) earnings per share for the current quarter, according to Zacks. Zacks has also assigned BioLineRx an industry rank of 93 out of 265 based on the ratings given to its competitors.
BLRX has been the subject of a number of research reports. Maxim Group cut BioLineRx from a “buy” rating to a “hold” rating and lowered their price target for the stock from $4.00 to $1.00 in a research report on Monday, August 8th. Roth Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of BioLineRx in a research report on Sunday, August 14th. Zacks Investment Research cut BioLineRx from a “buy” rating to a “hold” rating in a research report on Thursday, June 16th. Finally, S&P Equity Research lowered their price target on BioLineRx from $1.24 to $1.10 in a research report on Friday, September 23rd.
BioLineRx (NASDAQ:BLRX) opened at 1.06 on Wednesday. BioLineRx has a 1-year low of $0.71 and a 1-year high of $1.73. The company’s market cap is $59.81 million. The stock has a 50 day moving average price of $1.00 and a 200-day moving average price of $0.93.
BioLineRx (NASDAQ:BLRX) last posted its quarterly earnings data on Thursday, August 11th. The company reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by $0.02. On average, equities research analysts forecast that BioLineRx will post ($0.26) EPS for the current year.
A hedge fund recently raised its stake in BioLineRx stock. Menta Capital LLC increased its position in shares of BioLineRx Ltd. (NASDAQ:BLRX) by 11.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 98,917 shares of the company’s stock after buying an additional 10,400 shares during the period. Menta Capital LLC owned 0.18% of BioLineRx worth $101,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 12.46% of the company’s stock.
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.